Ionis Pharmaceuticals (IONS) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free IONS Stock Alerts $41.59 -0.25 (-0.60%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineabrdn plc Buys Shares of 136,419 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - April 27 at 5:25 AMIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbankmarketbeat.com - April 26 at 5:21 AMIonis Publishes 2023 Corporate Responsibility Reportprnewswire.com - April 25 at 7:00 AMIonis to hold first quarter 2024 financial results webcastprnewswire.com - April 23 at 7:05 AM24,779 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Strs Ohiomarketbeat.com - April 23 at 5:10 AMJoseph Baroldi Sells 4,006 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stockamericanbankingnews.com - April 19 at 5:38 AMIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 Sharesinsidertrades.com - April 18 at 6:32 AMQ1 2024 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Lowered by Analystamericanbankingnews.com - April 18 at 5:46 AMIonis Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.09 Per Share (NASDAQ:IONS)americanbankingnews.com - April 18 at 2:42 AMIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $166,649.60 in Stockmarketbeat.com - April 17 at 6:39 PMFY2026 EPS Estimates for Ionis Pharmaceuticals, Inc. Lifted by Leerink Partnrs (NASDAQ:IONS)marketbeat.com - April 17 at 6:35 PM24,243 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by HealthInvest Partners ABmarketbeat.com - April 16 at 6:50 PMIONS Quantitative Stock Analysisnasdaq.com - April 15 at 8:06 AMGranite Bay Wealth Management LLC Sells 34,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - April 14 at 12:00 PMWolfe upgrades Ionis to outperform, cites upcoming catalystsmsn.com - April 12 at 4:02 PMIonis Pharmaceuticals stock upgraded to Outperforminvesting.com - April 11 at 10:41 PMIonis Pharmaceuticals stock upgraded to Outperforminvesting.com - April 11 at 10:41 PMIonis Pharmaceuticals (NASDAQ:IONS) Lifted to Outperform at Wolfe Researchmarketbeat.com - April 10 at 8:17 AMIonis Pharmaceuticals (NASDAQ:IONS) Rating Reiterated by William Blairmarketbeat.com - April 9 at 11:22 AMIonis Pharmaceuticals (NASDAQ:IONS) Given New $75.00 Price Target at Oppenheimermarketbeat.com - April 9 at 8:49 AMIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Position Lessened by SG Americas Securities LLCmarketbeat.com - April 9 at 4:09 AMAnalysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)markets.businessinsider.com - April 9 at 2:25 AMIonis Pharmaceuticals Faces Sell Rating Amid Weak Clinical Results and Rising Competitionmarkets.businessinsider.com - April 8 at 9:24 PMBuy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for Olezarsenmarkets.businessinsider.com - April 8 at 4:24 PMIonis experimental drug meets key goal in familial chylomicronemia studymsn.com - April 8 at 4:24 PMIonis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromefinanznachrichten.de - April 8 at 8:52 AMIonis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeprnewswire.com - April 7 at 9:48 AMShort Interest in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Increases By 6.1%marketbeat.com - April 2 at 7:37 AMIonis to present at upcoming investor conferencesprnewswire.com - April 1 at 7:05 AMAssenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 30 at 4:51 AMIonis to hold olezarsen Phase 3 data webcastprnewswire.com - March 28 at 7:05 AMARK Investment Management LLC Sells 461,311 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 28 at 6:39 AMPositive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingprnewswire.com - March 25 at 8:18 AMIonis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?finance.yahoo.com - March 22 at 4:41 PMWellington Management Group LLP Raises Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 19 at 4:53 AMIONS Oct 2024 50.000 putca.finance.yahoo.com - March 17 at 9:00 PMNASH drug market expected to surpass $48B by 2035msn.com - March 16 at 1:30 PMIONS Apr 2024 75.000 callfinance.yahoo.com - March 16 at 8:29 AMQ4 2023 Agenus Inc Earnings Call and Corporate Updatefinance.yahoo.com - March 14 at 10:45 PMAnalysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)markets.businessinsider.com - March 14 at 10:45 PMMadrigal wins FDA approval of first drug for MASHfinance.yahoo.com - March 14 at 5:44 PMHudson Bay Capital Management LP Has $8.62 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 14 at 7:25 AMGenetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Showsbenzinga.com - March 13 at 12:50 PMIonis Pharma's fatty liver disease drug succeeds in mid-stage trialreuters.com - March 13 at 7:50 AMIonis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHfinance.yahoo.com - March 13 at 7:50 AMJacobs Levy Equity Management Inc. Sells 176,441 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 12 at 8:39 AMCytokinetics drifts lower as CEO touts standalone strategymsn.com - March 11 at 5:47 PMAre These 5 Undervalued Stocks Ready to Break Out?marketbeat.com - March 8 at 9:11 AMAre These 5 Undervalued Stocks Ready to Break Out? (IONS)marketbeat.com - March 8 at 9:10 AMEnvestnet Asset Management Inc. Increases Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)marketbeat.com - March 7 at 4:38 AM Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy IONS Media Mentions By Week IONS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.500.32▲Average Medical News Sentiment IONS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼55▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MDGL News Today ALKS News Today FOLD News Today GERN News Today DVAX News Today UTHR News Today TEVA News Today BMRN News Today ALNY News Today APLS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
